shape-zoom2 shape-zoom2 chevron-down edit share2 twitter youtube

Features

Highlighted Features

SWIPE

Latest Features

9/5/2017
7/19/2017
  • The Shape Of Drugs To Come

    Biotechnology opened the door to new types of medicines based on nature’s own building blocks. No company has done more to advance this revolution than Amgen, and the company’s broad toolkit of drug modalities just got larger.

    Learn more
6/1/2017
4/19/2017
  • The Future of Biotechnology

    Just as advances in physics and engineering transformed life in the 20th century, rapid progress in biology is poised to change the world in the decades to come. Amgen R&D leader Sean Harper describes a rapid series of breakthroughs that clearly show that science has entered the Biocentury.

    Learn more
3/1/2017
12/22/2016
  • A Gene Linked to Lower Risk of Heart Attacks

    A rare mutation discovered at Amgen subsidiary deCODE Genetics is associated with a 34 percent lower risk of coronary artery disease. Amgen scientists aim to turn this insight into a new type of heart drug, which might complement lipid-lowering drugs by addressing other potential risk factors for heart disease.

    Learn more
11/4/2016
  • Better Science Through Biosimilar R&D

    Amgen helped to develop the science used in making biologic medicines, and we remain a leader in designing and manufacturing new biologics. This experience is now being applied to the challenge of making high-quality biosimilars.

    Learn more
6/9/2016
  • The Hunt for Alzheimer’s Genes

    Amgen’s pursuit of Alzheimer’s treatments now includes a global collaboration with Novartis that focuses on the BACE gene, a target first cloned by Amgen and supported by genetic validation.

    Learn more
3/21/2016
2/17/2016
  • The Passionate Pursuit of Nav 1.7

    Recent research has shown that mutations in the gene for Nav 1.7, a sodium ion channel, can either ramp up pain or shut it down entirely. Amgen scientists are using creative approaches and unconventional tools to explore the potential of Nav 1.7 as a new drug target for pain.

    Learn more
12/08/2015
  • The Ultimate Parasite

    Amgen’s head of Discovery Research, Alexander Kamb, discusses his view on why we get cancer, what makes it so difficult to treat, and why immunotherapeutic approaches look so promising.

    Learn more
12/23/2014
  • The New Genetics

    Advances in human genetics are pinpointing genes that cause disease and providing a new way to identify highly relevant drug targets. There is strong evidence that genetically validated targets can boost clinical success rates, accelerate drug development timelines, and lower the overall cost of R&D. Through internal investments and the acquisition of deCODE Genetics, Amgen has become a leader in gene-driven R&D. These new capabilities have helped Amgen to accelerate key programs, strengthen its pipeline, and build a Discovery portfolio featuring novel targets strongly linked to disease risk.

    Learn more

Features

previous